Related Experiment Video
Updated: Aug 24, 2025
A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
Published on: January 22, 2016
Methylphenidate for prison inmates with ADHD: yes or no?
1School of Psychology, Centre for Innovation in Mental Health (CIMH), Faculty of Environmental and Life Sciences, University of Southampton, UK; Solent NHS Trust, Southampton, UK; Hassenfeld Children's Hospital at NYU Langone, New York University Child Study Center, New York, New York, USA; and Division of Psychiatry and Applied Psychology, School of Medicine, University of Nottingham, UK.
Response rates for ADHD medication in prisoners were similar for methylphenidate and placebo. This analysis critically examines the trial
Area of Science:
- Psychiatry
- Clinical Psychology
- Pharmacology
Background:
- A double-blind randomized controlled trial investigated the efficacy of osmotic-release oral system methylphenidate (OROS-methylphenidate) in prisoners with attention-deficit hyperactivity disorder (ADHD).
- The study reported similar response rates (~50%) for both OROS-methylphenidate and placebo groups.
Discussion:
- This critical discussion evaluates the Asherson et al. trial in the context of existing international literature on ADHD treatment.
- Key issues concerning clinical practice and research methodologies in treating ADHD within correctional settings are highlighted.
Key Insights:
- The observed similarity in response rates between OROS-methylphenidate and placebo raises questions about treatment efficacy in this specific population.
- Critical analysis suggests potential confounding factors or limitations in the trial design or interpretation.
Outlook:
- Further research is needed to understand the nuances of ADHD treatment in incarcerated individuals.
- Exploring alternative or adjunctive therapeutic strategies may be beneficial for this population.
More Related Videos
10:02Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD
Published on: March 12, 2020
07:51A Protocol for Measuring Cue Reactivity in a Rat Model of Cocaine Use Disorder
Published on: June 18, 2018
Related Concept Videos
01:28Adrenergic Agonists: Mixed-Action Agents
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
01:30Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
01:30Adrenergic Agonists: Therapeutic Uses
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
01:24CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
01:25Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...